Spyre Therapeutics, Inc. (SYRE)
Total Valuation
SYRE has a market cap or net worth of $990.58 million. The enterprise value is $650.98 million.
Market Cap | 990.58M |
Enterprise Value | 650.98M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, before market open.
Earnings Date | May 9, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
SYRE has 36.15 million shares outstanding. The number of shares has increased by 104.59% in one year.
Shares Outstanding | 36.15M |
Shares Change (YoY) | +104.59% |
Shares Change (QoQ) | +60.63% |
Owned by Insiders (%) | 5.51% |
Owned by Institutions (%) | 49.50% |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1,118.03 |
Forward PS | n/a |
PB Ratio | 5.38 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 734.74 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.68, with zero debt.
Current Ratio | 10.68 |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -160.40% |
Return on Capital (ROIC) | -131.67% |
Revenue Per Employee | $29,533 |
Profits Per Employee | -$11.29M |
Employee Count | 30 |
Asset Turnover | 0.00 |
Inventory Turnover | n/a |
Taxes
Income Tax | -26,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +417.96% in the last 52 weeks. The beta is 2.85, so SYRE's price volatility has been higher than the market average.
Beta (1Y) | 2.85 |
52-Week Price Change | +417.96% |
50-Day Moving Average | 30.48 |
200-Day Moving Average | 17.80 |
Relative Strength Index (RSI) | 54.95 |
Average Volume (30 Days) | 481,119 |
Short Selling Information
The latest short interest is 2.88 million, so 7.96% of the outstanding shares have been sold short.
Short Interest | 2.88M |
Short Previous Month | 2.15M |
Short % of Shares Out | 7.96% |
Short % of Float | n/a |
Short Ratio (days to cover) | 2.51 |
Income Statement
In the last 12 months, SYRE had revenue of $886,000 and -$338.79 million in losses. Loss per share was -$49.12.
Revenue | 886,000 |
Gross Profit | 886,000 |
Operating Income | -242.30M |
Pretax Income | -338.82M |
Net Income | -338.79M |
EBITDA | -337.85M |
EBIT | -338.82M |
Loss Per Share | -$49.12 |
Balance Sheet
The company has $339.60 million in cash and no debt, giving a net cash position of $339.60 million or $9.39 per share.
Cash & Cash Equivalents | 339.60M |
Total Debt | n/a |
Net Cash | 339.60M |
Net Cash Per Share | $9.39 |
Equity / Book Value | 184.02M |
Book Value Per Share | 5.09 |
Working Capital | 309.55M |
Cash Flow
In the last 12 months, operating cash flow was -$99.91 million and capital expenditures $475,000, giving a free cash flow of -$99.44 million.
Operating Cash Flow | -99.91M |
Capital Expenditures | 475,000 |
Free Cash Flow | -99.44M |
FCF Per Share | -$14.42 |
Margins
Gross margin is 100.00%, with operating and profit margins of -27,347.97% and -38,238.15%.
Gross Margin | 100.00% |
Operating Margin | -27,347.97% |
Pretax Margin | -38,241.08% |
Profit Margin | -38,238.15% |
EBITDA Margin | -38,132.28% |
EBIT Margin | -38,241.08% |
FCF Margin | -11,222.91% |
Dividends & Yields
SYRE does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -104.59% |
Shareholder Yield | -104.59% |
Earnings Yield | -34.20% |
FCF Yield | -10.04% |
Analyst Forecast
The average price target for SYRE is $38.00, which is 0.18% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $38.00 |
Price Target Difference | 0.18% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -33.74% |
Stock Splits
The last stock split was on September 8, 2023. It was a reverse split with a ratio of 1:25.
Last Split Date | Sep 8, 2023 |
Split Type | Reverse |
Split Ratio | 1:25 |
Scores
SYRE has an Altman Z-Score of 2.8 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.8 |
Piotroski F-Score | 2 |